TEVA-TIAPROFENIC ACID TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

TIAPROFENIC ACID

可用日期:

TEVA CANADA LIMITED

ATC代码:

M01AE11

INN（国际名称）:

TIAPROFENIC ACID

剂量:

200MG

药物剂型:

TABLET

组成:

TIAPROFENIC ACID 200MG

给药途径:

ORAL

每包单位数:

100/500/1000

处方类型:

Prescription

治疗领域:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

產品總結:

Active ingredient group (AIG) number: 0115902001; AHFS:

授权状态:

APPROVED

授权日期:

2011-05-06

产品特点

_TEVA-TIAPROFENIC ACID (Tiaprofenic acid) _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA–TIAPROFENIC ACID
Tiaprofenic Acid Tablets
Tablets, 200 mg and 300 mg, for oral use
Teva Standard
Non-Steroidal Anti-Inflammatory Drug (NSAID)
Teva Canada Limited
Date of Initial Authorization:
30 Novopharm Court
December 31, 1996
Toronto, ON
M1B 2K9
Date of Revision:
Canada
August 15, 2022
www.tevacanada.com
Submission Control No.: 261587
_TEVA-TIAPROFENIC ACID (Tiaprofenic acid) _
_Page 2 of 39_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
08/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
08/2022
7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests,
_Pregnancy_
08/2022
7 WARNINGS AND PRECAUTIONS, Skin, _Serious skin reactions_
08/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
08/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................................
4
1
INDICATIONS
.....................................................................................................................
4
1.1
PEDIATRICS
................................................................................................................
4
1.2
GERIATRICS
................................................................................................................
4
2
CONTRAINDICATIONS........................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................... 5
4
DOSAGE AND ADMINISTRATION
..........................................................................